Status:
TERMINATED
Study Evaluating Multiple Ascending Dose in Schizophrenia Patients
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborating Sponsors:
Solvay Pharmaceuticals
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.
Eligibility Criteria
Inclusion
- Men, aged 18-50 years old
- Women, aged 18-50 years old
Exclusion
- Non-lactating women, aged 18-50 years old
- Non-pregnant women, aged 18-50 years old
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2008
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00620568
Start Date
February 1 2008
End Date
March 1 2008
Last Update
August 4 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.